We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Study Confirms Link Between Low Cholesterol and Parkinson's Disease

By Biotechdaily staff writers
Posted on 21 Apr 2008
An international team of neurologists and cardiovascular researchers has released data showing that reduced levels of LDL-cholesterol, which are good from the point of view of the cardiologist, actually increase the risk of developing Parkinson's disease.

The data linking LDL-cholesterol to Parkinson's disease was obtained from the 1991 to 1993 Honolulu-Asia Aging Study in which the lipid profiles of a group of 3233 men of Japanese ancestry were evaluated. More...
The health of the participants was then monitored for an additional 10 years with the aim of determining any linkage between cholesterol levels and development of Parkinson's disease.

The results published in the March 31, 2008, issue of the journal Movement Disorders revealed that after adjusting the statistical analysis for age, smoking, coffee intake, and other factors, the relative odds for developing Parkinson's disease for those with lower LDL levels (85 milligrams per deciliter) was about twice that of those with higher LDL levels (135 milligrams per deciliter).

"This finding gives us one more piece in the puzzle about the role of cholesterol in Parkinson's disease,” said first author Dr. Xuemei Huang, assistant professor of neurology at the University of North Carolina (Chapel Hill, USA). "Our study again shows an association between low cholesterol and the risk of Parkinson's disease, but we have not shown cause and effect. What makes these results especially useful is the fact that most of the men in this study were not taking cholesterol-lowering drugs such as statins. This suggests that the association between low LDL levels and Parkinson's exists independently from statin use. People taking statins for valid medical reasons should not stop simply to avoid Parkinson's.”


Related Links:
University of North Carolina

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.